A stock market site by Business Insider with real-time data, custom charts and breaking news. Get the latest on stocks, commodities, currencies, funds, rates, ETFs, and more.

  • 31,385articles · 365d
  • 4+ hour agolatest article
  • Sep 13, 2025earliest in window
  • 93%with images
  • 290avg words
articles per day
Categories
  • Economy, Business & Finance 26,602
  • Finance & Business 22,239
  • News 10,075
  • Finance 4,953
  • Business & Industrial 4,917
  • Health & Wellness 3,722
  • Medical 2,567
  • Computers & Electronics 1,146

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

markets.businessinsider.com
markets.businessinsider.com > news > stocks > nanoxtreme-helps-30-000-people-in-24-months-through-nano-delivery-pain-relief-1036431775

NanoXtreme Helps 30,000 People in 24 Months Through Nano-Delivery Pain Relief

1+ mon, 5+ day ago   (226+ words) The 24-month-old brand uses a nano-delivery system designed to carry 19 natural ingredients deeper than conventional topical creams. United States, August 8, 2026 -- NanoXtreme leverages nano-technology to enhance the absorption process of their pain cream into the body. Co-founded in 2024 by Matt Grondahl,…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > pacira-biosciences-announces-new-national-survey-revealing-the-hidden-toll-of-pain-on-america-s-workforce-1036371669

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

1+ mon, 2+ week ago   (490+ words) - Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options - The findings presented are based on a survey of 1,000 U.S. adults employed full-time in occupations that require…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > artiva-biotherapeutics-highlights-allonk-data-presented-at-eular-2026-fda-rmat-designation-in-refractory-rheumatoid-arthritis-and-webcast-today-1036231499

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

3+ mon, 5+ day ago   (181+ words) As of the April 3, 2026, data cutoff, patients demonstrated clinically meaningful improvements in disease activity measures across RA, SjD and SSc. The presentation also highlighted translational evidence of deep B-cell depletion, supporting AlloNK’s potential as an outpatient-administered regimen designed to be…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > the-neck-cloud-announces-cervical-decompression-device-for-tech-neck-neck-pain-1036242893

The Neck Cloud Announces Cervical Decompression Device For Tech Neck & Neck Pain

3+ mon, 1+ day ago   (360+ words) markets.businessinsider.com The Neck Cloud Announces Cervical Decompression Device For Tech Neck & Neck Pain The Neck Cloud has announced a cervical traction device designed to address tech neck in desk workers through a three-way system combining cervical traction, acupressure,…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > college-student-posture-correction-neck-pain-relief-cervical-traction-update-1036194440

College Student Posture Correction & Neck Pain Relief: Cervical Traction Update

3+ mon, 2+ week ago   (302+ words) The Neck Cloud announces updates to its cervical traction device, designed to relieve neck pain and improve posture in college students and professionals. Sheridan, United States, May 26, 2026 -- Cervical traction device brand The Neck Cloud has announced an update to its…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > cervical-traction-device-for-neck-pain-tmj-tension-headaches-product-updated-1036125600

Cervical Traction Device For Neck Pain, TMJ & Tension Headaches: Product Updated

4+ mon, 5+ day ago   (422+ words) markets.businessinsider.com Cervical Traction Device For Neck Pain, TMJ & Tension Headaches: Product Updated The Neck Cloud has updated its lab-tested cervical traction device with a three-way system combining cervical traction, acupressure, and sub-occipital muscle stimulation — developed over three years…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > liberty-physical-therapy-wellness-celebrates-15-years-of-serving-jersey-city-with-integrated-patient-centered-care-1036094447

Liberty Physical Therapy & Wellness Celebrates 15 Years of Serving Jersey City with Integrated, Patient-Centered Care

4+ mon, 1+ week ago   (377+ words) Jersey City’s top-rated PT clinic celebrates a 15-year milestone of delivering personalized,non-surgical physical therapy to patients of all ages Jersey City, NJ, May 1, 2026 -- Liberty Physical Therapy & Wellness is proud to celebrate 15 years of providing comprehensive physical therapy in Jersey…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > biorestorative-therapies-to-present-new-data-at-isct-2026-highlighting-its-ongoing-phase-2-clinical-trial-in-chronic-lumbar-disease-and-its-biocosmeceutical-platform-1036087380

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

4+ mon, 1+ week ago   (420+ words) BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX,…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > mesoblast-achieves-patient-recruitment-target-in-pivotal-phase-3-trial-for-chronic-low-back-pain-1036074660

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

4+ mon, 2+ week ago   (421+ words) The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or sham control for 12 months. The trial seeks to confirm results from the earlier MSB-DR003 trial where a single intra-discal injection of rexlemestrocel-L…...

markets.businessinsider.com
markets.businessinsider.com > news > stocks > dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and-neuropathy-1036024786

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

4+ mon, 3+ week ago   (585+ words) Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National…...